Report error Found 702 Enz. Inhib. hit(s) with Target = 'Serine/threonine-protein kinase Chk2'
Displayed 1 to 50 (of 702 total ) | Next | Last >>
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of human recombinant Chk2More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:The compounds of the present disclosure used in the experiments were self-prepared, and their chemical names and structural formulas were shown in th...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.30nMAssay Description:Inhibition of recombinant human Chk2 kinaseMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of CHK2 by DELFIA assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.30nMAssay Description:Inhibition of CHK2 using biotinylated substrate preincubated for 15 mins before substrate addition measured after 30 mins by fluorescence microplate ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Inhibition of recombinant human Chk2 kinaseMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.40nMAssay Description:Inhibition of recombinant human Chk2 kinaseMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.5nMAssay Description:Inhibition of recombinant human Chk2 kinaseMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 4.90nMAssay Description:Inhibition of CHK2 (unknown origin)More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of CHK2 by DELFIA assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.10nMAssay Description:Inhibition of CHK2 (unknown origin)More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.5nMAssay Description:Inhibition of recombinant human Chk2 kinaseMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.5nMAssay Description:Inhibition of Chk2 (unknown origin) by ELISA based spectrophotometric analysisMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.60nMAssay Description:Inhibition of Chk2 (unknown origin) assessed as decrease in Cdc25C phosphorylation at Ser216 by ELISA based spectrophotometric analysisMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.60nMAssay Description:Inhibition of Chk2 (unknown origin) assessed as decrease in Cdc25C phosphorylation at Ser216 by ELISA based spectrophotometric analysisMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.70nMAssay Description:Inhibition of human CHK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 6.60nMAssay Description:Inhibition of recombinant human Chk2 kinaseMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 6.90nMAssay Description:Inhibition of Chk2 (unknown origin) by ELISA based spectrophotometric analysisMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKd: 7.10nMAssay Description:Binding affinity to CHEK2More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of Chk2 (unknown origin)More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of CHK2 by DELFIA assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of CHK2 (unknown origin)More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of human Chk2 using STK1 as substrate after 10 mins by HTRF assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:In vitro inhibitory concentration against checkpoint kinase 2 (Chk2) by using [gamma-33P]-ATP] as radioligandMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8.20nMAssay Description:Inhibition of recombinant human Chk2 kinaseMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of CHK2 by DELFIA assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 9.20nMAssay Description:Inhibition of human CHK2 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 9.80nMAssay Description:Inhibition of recombinant human Chk2 kinaseMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetSerine/threonine-protein kinase Chk2(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL









































